Syndax Pharmaceuticals (SNDX) Return on Sales (2015 - 2026)

Syndax Pharmaceuticals' Return on Sales history runs 11 years deep, the most recent figure standing at 0.0% for Q1 2026.

• In Q1 2026, Return on Sales rose 3.0% year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.01% (up 6.0% YoY), while the FY2025 annual figure was 0.01%, up 12.0% from the prior year.
• Return on Sales was 0.0% for Q1 2026 at Syndax Pharmaceuticals, up from 0.01% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.0% in Q1 2026 to a low of 0.19% in Q2 2024.
• Historically, Return on Sales has averaged 0.05% across 4 years, with a median of 0.02% in 2023.
• The sharpest annual moves came in 2024 and 2025: Return on Sales retreated 18 bps in 2024, then increased 18 bps in 2025.
• A 4-year view of Return on Sales shows it stood at 0.02% in 2023, then tumbled by 603 bps to 0.12% in 2024, then soared by 93 bps to 0.01% in 2025, then jumped by 44 bps to 0.0% in 2026.
• The last three Return on Sales figures came in at 0.0% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.